References
1
Ross SA, Ziska DS, Zhoa K, et al. Variance of common flavonoids by brand of grapefruit juice.
Fitoterapia. 2000;71:154-161.
2
Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Angiology. 1994;45:574-578.
3
Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Angiology. 1994;45:566-573.
4
Thanapongsathorn W, Vajrabukka T. Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids.
Dis Colon Rectum. 1992;35:1085-1088.
5
Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids.
Br J Surg. 2000;87:868-872.
6
Ho YH, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial.
Dis Colon Rectum. 2000;43:66-69.
7
Tsouderos Y. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
Z Kardiol. 1991;80(suppl 7):95-101.
8
Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial.
Eur J Clin Pharmacol. 1996;50:443-447.
9
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Angiology. 1997;48:77-85.
10
Guilhou JJ, Fevrier F, Debure C, et al. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial.
Int J Microcirc Clin Exp. 1997;17(suppl 1):21-26.
11
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Angiology. 1997;48:77-85.
12
Guilhou JJ, Fevrier F, Debure C, et al. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial.
Int J Microcirc Clin Exp. 1997;17(suppl 1):21-26.
13
Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
Int Angiol. 1993;12:69-72.
14
Pecking AP, Fevrier B, Wargon C, et al. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer).
Angiology. 1997;48:93-98.
15
Lee SH, Park YB, Bae KH, et al. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: cholesterol acyltransferase in rats.
Ann Nutr Metab. 1999;43:173-180.
16
Shin YW, Bok SH, Jeong TS, et al. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats.
Int J Vitam Nutr Res. 1999;69:341-347.
17
Emim JA, Oliveira AB, Lapa AJ. Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice.
J Pharm Pharmacol. 1994;46:118-122.
18
Manuel y Keenoy B, Vertommen J, De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients.
Diabetes Nutr Metab. 1999;12:256-263.
19
Middleton E Jr, Drzewiecki G, Tatum J. The effects of citrus flavonoids on human basophil and neutrophil function.
Planta Med. 1987;53:325-328.
20
So FV, Guthrie N, Chambers AF, et al. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices.
Nutr Cancer. 1996;26:167-181.
21
Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Angiology. 1994;45:574-578.
22
Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Angiology. 1994;45:566-573.
23
Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids.
Br J Surg. 2000;87:868-872.
24
Ho YH, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial.
Dis Colon Rectum. 2000;43:66-69.
25
Thanapongsathorn W, Vajrabukka T. Clinical trial of oral diosmin (DaflonŴ) in the treatment of hemorrhoids.
Dis Colon Rectum. 1992;35:1085-1088.
26
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Angiology. 1997;48:77-85.
27
Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial.
Eur J Clin Pharmacol. 1996;50:443-447.
28
Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
Int Angiol. 1993;12:69-72.
29
Miller MJ. Injuries to athletes. Evaluation of ascorbic acid and water soluble citrus bioflavonoids in the prophylaxis of injuries in athletes.
Med Times. 1960;88:313-316.
30
Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Angiology. 1994;45:579-584.
31
Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy.
Int J Gynaecol Obstet. 1997;57:145-151.
32
Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer.
J Natl Cancer Inst. 1999;91:354-359.
33
Strick R, Strissel PL, Borgers S, et al. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia.
Proc Natl Acad Sci. 2000;97:4790-4795.
34
Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
Int Angiol.
1988;7:39-43.
35
Danielsson G, Jungbeck C, Peterson K, et al. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
Eur J Vasc Endovasc Surg.
2002;23:73-76.
36
Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation.
Curr Med Chem. 2001;8:135-153.
37
Cluzan RV, Alliot F, Ghabboun S, et al. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT.
Lymphology. 1996;29:29-35.
38
La Torre F, Nicolai AP. Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial.
Dis Colon Rectum. 2004 Mar 25. [Epub ahead of print]
39
Colak T, Akca T, Dirlik M, et al. Micronized flavonoids in pain control after hemorrhoidectomy: a prospective randomized controlled study.
Surg Today. 2003;33:828-832.
40
Cesarone MR, Belcaro G, Pellegrini L, et al. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study.
Angiology. 2005;56:1-8.
41
Liu B, Edgerton S, Yang X, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention.
Cancer Res. 2005;65:879-886.
42
Reshef N, Hayari Y, Goren C, et al. Antihypertensive effect of sweetie fruit in patients with stage I hypertension.
Am J Hypertens.
2005;18:1360-1363.
43
Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, et al. Meta-analysis of flavonoids for the treatment of haemorrhoids.
Br J Surg.
2006 May 31 [Epub ahead of print].
44
Yeum CH, Choi JS. Effect of naringin pretreatment on bioavailability of verapamil in rabbits.
Arch Pharm Res. 2006;29:102-107.
45
Lotito SB, Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?
Free Radic Biol Med. 2006;41:1727-1746.
46
Tang NP, Zhou B, Wang B, Yu RB, Ma J. Flavonoids intake and risk of lung cancer: a meta-analysis.
Jpn J Clin Oncol.
2009;39:352-359.